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Abstract
Monocyclic and Bicyclic aromatic heterocycles such as imidazoles, thiazoles, thiadiazoles,
oxazoles, oxadiazoles quinazolines, indoles, benzimidazoles, purines pyrido[4,3-d]pyri‐
midines, thiazolo[5,4-d]pyrimidines, thiazolo[4,5-d]pyrimidines, oxazolo[5,4-d]pyrimi‐
dines and thieno[2,3-d]pyrimidines are renowned pharmacophores in drug discovery.
These special structures are well explained and exemplified in chemical compound libra‐
ries. In this chapter, several types of thiazole based heterocyclic scaffolds such as mono‐
cyclic or bicyclic systems synthesis and their biological activities studies are presented,
which are not frequently present in books and reviews. We mention the first importance
of synthetic route of various thiazole based compounds and their applications in medici‐
nal chemistry in this chapter.
Keywords: Thiazole, privileged structures, thiazolopyridine, thiazolopyrimidines
1. Introduction
Currently, the whole pharmaceutical industry is encountered with the challenge of enhancing
work rate and advancement. The key obstacles are the increasing expenses of exploration and
expansion and a concurrent deteriorating amount of new chemical entities (NCEs). The source
of this modernism shortfall is not the biology. Interpreting of the human genome has directed
to a prosperity of drug targets. With the addition of more than 35,000 human genes, the
hypothesis is that at least 2,000 are significantly tangled in the occurrence and progress of the
illness. Moreover, since each of these genes is associated with the usefulness of between five
and ten proteins, the deduction is that their potency be 5,000 – 10,000 aims for innovative drugs
[1,2]. Even though the positive outline of protein therapeutics and the aptitude of gene therapy,
key pharmaceutical establishments are even focused on research and growth of small molec‐
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ular mass compounds. Therefore, the challenge is to choose the greatest drugable objectives
and formulate the conforming drug-like molecules.These materials are not only relative to the
mark but also have precise pharmacokinetic and toxicological properties, which was allowed
to be established as a drug. Medicinal chemistry as a scientific discipline has introduced several
new techniques over the last few years to the rapidity of the drug discovery process, such as
combinatorial chemistry, microwave-assisted organic synthesis, and high - output refinement
[3]. Despite the stable rise in R & D, the total number of NCE successes in the market has
reduced fundamentally. It appears clearly that choosing the suitable molecules to synthesize
is one of the most difficult queries. It has been projected that the sum of potential compounds
with molecular weight of lower than 500 Da is 10200, where only 1060 may retain drug-like
applications. The percentage of molecules prepared untill today has been projected as one part
in 1058 or approximately the fraction of the mass of the proton to the mass of the sun. The
concern is, therefore, the selection of new molecules from this vast universe that have the
potential to be biologically active [4]. To build a new drug discovery mission and to discover
the bioactive compounds, various possibilities are offered. Triumphs can be achieved via a
virtual screening method or can be simulated from technical or manifest literature. Most often
than not, drug innovation projects start with a high quantity screening operation of commer‐
cially accessible compound collections besides targeting curiosity. It became clear in recent
years that combinatorial libraries are not distinct enough. As the core attention of the Labora‐
tory of Medicinal Chemistry showed in the synthesis and biological evaluation of bicyclic
aromatic heterocycles [5], it is scrutinized that the number of accessible bicyclics heterocycles
is principally restricted to a well-known nitrogen enclosing compounds, such as pyrimidines,
thioazoles, coumarins, thiozlopyridines and benzothiazole (Figure 1).
 
α
Figure 1. Examples of privileged structures
In vision of the significance of thiazoles and their derivatives, numerous approaches for its
synthesis were developed by various groups such as Hantzsch [6], Tchernic [7], Cook-Heilborn
and Gabriel [8].
A thiazole ring system originates naturally in the crucial water soluble vitamin thiamin, also
known as Vitamin B1, which supports the discharge of energy from carbohydrates through
the course of metabolism. The occurrence of thiazole ring in vitamin B1 and its coenzyme play
a significant role in the decarboxylation of α-keto acids and as an electron sink, respectively
[9]. It also assist in the regular operational of the nervous system through its character in the
synthesis of acetylcholine, a neurotransmitter.
Thiazole ring system appears in the bacitracin and penicillin antibiotics and various synthetic
drugs. Synthetic drugs belonging to the thiazole family consist of the antimicrobial agents
acinitrazole (1) and sulfathiazole [10], (2) antibiotic penicillin [11], (3) antidepressant prami‐
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pexole [12], (4) antineoplastic agents Bleomycin (5) and Tiazofurin [13], (6) anti-HIV drug
Ritonavir [14], (7) the antiasthmatic drug cinalukast [15], (8) antiulcer agent Nizatidine [16]
(9). Additionally, extensively used thiazole derivatives are the non-steroidal immunomodu‐
latory drug Fanetizole [17] (10) and anti-inflammatory drug Meloxicam [18] (11). Thiazole
derivatives with polyoxygenated phenyl module have exhibited encouraging anti-fungal
activity [19]. Thiazoles found from microbial, and marine ancestries reveal antitumor and
antiviral activities. Thiazole is recognized as ligand of estrogen receptors [20] and also as
unique kind of antagonists for adenosine receptors [21].
α
 
α
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Other substantial thiazoles take account of essential dyes and fungicides or nematicide,
Tricyclazole 12, Thiabendazole 13, and Thifluzamide 14 are promoted for the switch of several
agricultural pests [22,23]. Primuline yellow 15 and Rhodanine red 16 dyes are some of the best
models of thiazole moiety containing dyes [24,25]. Numerous thiazoles are flavor materials
and also originate in roasted peanuts. They materialized in foods by the exploit of sulfur-
containing amino acids interacting with carbohydrates. Thiazoles are surrounded by some
significant heterocyclic compounds that give the flavor of fermented coffee [26].
 
The exhilarating outcomes of the 2,4-disubstituted thiazoles as a unique class of Src Homology
2 (SH2) inhibitors for the behavior of osteoporosis and breast cancer have also been reported
[27]. Selection of the 2,4-disubstituted thiazoles as concealed pharmacophores for diacylhy‐
drazine of SC-51089, a prospective PGE2 antagonist have also been described [28]. With these
results, the thiazole ring system proves to be a well-known structural motif that originate in
several pharmaceutical agents and natural products extracted from various plants and marine
systems.
2. Structure of Thiazole
The structure of thiazole is reflected as the resonance amalgam of the subsequent resonating
structures (Figure 1). However, some of the resonating structures are also probable with the
contribution of d-orbitals of the sulfur atom.
 
Figure 2. Resonating Structures of Thiazole
The p-bond orders quantified by molecular orbital methods have specified thiazole molecule
to be aromatic with some dienic nature. Localization energies have projected reducing order
of the nucleophilic reactivities following the order: 2 > 5 > 4 and the electrophilic reactivities
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as: 5 > 2 > 4. Three hydrogen atoms present in the thiazole are anticipated to have the order of
acidity as H2 >> H5 > H4.
3. Synthesis of Thiazole
In the assessment of the significance of thiazoles and their derivatives, numerous techniques
for the synthesis of thiazole derivatives were established by various research groups such as
Hantzsch [6], Tchernic [7], Cook-Heilborn and Gabriel [8]. Lately, thiazole derivatives were
generated in the presence of various catalysts such as ammonium-12-molybdophosphate [29],
cyclodextrins [30], iodine [31] and silica chloride [32] in organic solvents at higher temperature
and solvents such as 1-methyl-2-pyrrolidinone [33], with the use of a microwave [34]. Numer‐
ous procedures for the synthesis of thiazole compounds are accessible, which can be catego‐
rized into the part structures demonstrated below. The earliest of these structures is observed
to be the most significant and highly flexible of all the thiazole formation techniques. With a
workable and first reactants, it approves alkyl, aryl, aralkyl or heterocycles to be taken in any
one of the 2-, 3-, 4- or 5-carbons of the thiazole ring. This technique, better acknowledged by
the name of the German chemist Hantzsch, who invented it in 1887, contains the condensation
of a compound bearing the two heteroatoms on the same carbon with a compound attached
one halogen and one carbonyl function on two adjacent carbon atoms. A boundless diversity
of compounds may assist as nucleophilic reagent in this reaction, such as thiourea, thioamide,
ammonium thiocarbamate or dithiocarbamate and its derivatives [35].
 
α
α
3.1. Synthesis from α-halocarbonyl compounds (Type Ia): Hantzsch’s synthesis.
First designated in 1887 by Hantzsch, the cyclization of α-halo carbonyl compounds by a wide
diversity of reactants attached to the N-C-S portion of the ring is the most extensively popular
process for formation of thiazoles. α α
Br
OR1
R2 S R3
NH2
+
N
S
R3
R1
R2  
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3.1.1. Reactions with Thioamides
3.1.1.1. Chloroacetaldehyde and derivatives
Thiazole ready to obtain by condensing thioformamide and chloroacetaldehyde [36,37].
 
α
α
α
α
3.1.1.2. Condensation with higher thioamides (2,4-Disubstituted and 2,4,5-trisubstituted thiazoles)
The reaction between thioamide and various α-halocarbonyl compounds has been utilized
broadly, and numerous thiazoles with alkyl, aryl, arylalkyl or heteroaryl of several functional
groups at 2-, 4- or 5-positions have been published. α
 
α
α
α
3.1.2. Reactions with N-substituted Thiourea
3.1.2.1. N-monosubstituted thioureas
The 2-monosubstituted or disubstituted aminothiazoles obtained reaction between Halo
carbonyl and N-substituted thiourea compounds [38].
α
 
α
α
α
3.1.3. Reaction with salts and esters of thiocarbamic acid: 2-hydroxy thiazoles and derivatives
This technique, originated by Marchesini [39,40], in 1893 involves the condensation of a α-
halocarbonyl compound with ammonium thiocarbamate to give 2-hydroxythiazole deriva‐
tives.
α
α
 
α
α
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3.2. Thiazoles formation from reorganization of the α-thiocyanatoketones
The simple cyclic reaction of α-thiocyanatoketones in aqueous acid concentrated sulfuric acid
in acetic acid, and water or alkaline solution gives to 2-hydroxy thiazoles after dilution in water.
These reactions can be conceded out for various hours at room temperature or by refluxing
for 1 or 2 hrs on a water bath [41-45].
 
α
α
α
α
α
α-Thiocyanatoacetophenone reacts thioacid to yield 2-mercapto-4-phenyl thiazole.
α
 
α
α
α
α
α-Thiocyanatoketones highly react with alkyl amine or ammonium chloride to provide their
N-substituted derivatives or 2-aminothiazoles [46].
α
α
 
α
α
α
3.3. Thiazoles from α-aminonitriles (Cook-Heilbron’s synthesis) (Type-II)
This category of synthesis, which was examined by Cook, Heilbron [47-49] give 5-aminothia‐
zoles differently substituted in the 2-position by reacting with an aminonitrile with salts and
esters of dithioacids, carbon oxysulfide, carbon disulfide, and isothiocyanates under remark‐
ably very mild conditions.
3.3.1. Carbon disulfide: 2-mercapto-5-aminothiazole derivatives
Carbon disulfide freely responds with α-aminonitriles giving 2-mercapto-5-amino thiazoles
[50,51], which can be transformed into 5-amino thiazoles unsubstituted in the 2-position.
α
α
α
 
α
3.3.2. Esters and salts of dithioacids: 5-aminothiazole compounds and related condensations
By reducing the salts or the esters of both dithioformic and dithiophenacetic acids with α -
aminonitriles, 5-aminothiazoles were achieved in better yields [52]. These reactions have
agreed in aqueous ethereal solution at ambient temperature.
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3.4. Thiazoles from acylaminocarbonyl compounds and phosphorus pentasulfide and
related condensation (Gabriel’s synthesis) (Type III)
This reaction was originally designated by Gabriel [53] in 1910 phosphorus pentasulfide
reacted with acylaminoketone (showed in below reaction) an equimolecular quantity to yield
2-phenyl-5-alkyl-thiazole. The reaction is analogous to the synthesis of additional five-
membered oxygen and sulfur holding rings from 1,4-dicarbonyl compounds.
 
α
α α
α
α
α
α α
α
3.5. Thiazoles from nitriles and α-mercaptoketones: 2,4-disubstituted and 2,4,5-
trisubstituted derivatives
Also, α-halocarbonyl compounds and α-mercaptoketones react with nitriles and aldehyde
oximes in the presence of an acid as catalyzed reaction for the synthesis of thiazoles.
3.5.1. 2,4,5-Trisubstituted thiazoles from α-mercaptoketones and nitriles
Miyatake and Yashikawa synthesized numerous 2,4,5-trisubstituted thiazoles and gave low
yield (16 to 40%) by the interaction of α-mercaptoketones on nitriles. Asinger and Thiel [54]
utilized an aldehyde and ammonia as an alternative for nitrile.
α
α α
α
α
 
α
α α
α
3.5.2. 2,4-Diaminothiazole derivatives from α-halonitriles and thiourea
α-Halonitrile can substitute α-halogenocarbonyl compounds in the Hantzsch’s synthesis
[55-57], thus, the reaction of thiourea with a α-halonitrile in refluxing alcohol provides 2,4-
diaminothiazoles.
α
α α
α
α
α
α α
α
 
Scope of Selective Heterocycles from Organic and Pharmaceutical Perspective8
3.6. Thiazoles from Vinyl Bromide
Thiazoles holding a variability of substituents such as aliphatic, aromatic, heterocyclic, or
alkenyl groups can be synthesized by an intramolecular nucleophilic substitution reaction of
N-(2-bromoprop-2-enyl)thioamides [58]. This vinylic substitution technique would afford an
exclusive synthetic method for a range of heterocycles.
 
3.7. Synthesis of 2,4-disubstituted-5-acetoxythiazoles
From the viable existing methyl benzoate derivatives and with racemic phenyl glycine, a range
of 2,4- disubstituted-5-acetoxythiazoles obtained in worthy to reasonable yields exhausting
the succeeding scheme [59]. Due to the excellent thermal stability of the thiazole nucleus, the
polymers integrating thiazole ring protocol have also been prepared.
 
4. Biological importance of thiazoles
Thiazole moiety-containing compounds invention present an extensive range of applications
in medicinal chemistry such as antibiotics, bacteriostatics, CNS regulants to high selling
diuretics [60-64]. Thiazole framework has established wide application in drug growth for the
treatment of hypertension [65], inflammation [66] and HIV infections [67]. Aminothiazoles are
famous for being ligands of estrogen receptors [68] as well as a innovative type of adenosine
receptor antagonists [69]. Other equivalents are utilized as fungicides, inhibiting in vivo
progress of Xanthomonas, as a component of herbicides or as schistosomicidal and anthel‐
mintic drugs [70].
Sherif. et al. [71] syntheses of two series of compounds that is thiazolylantipyrines and
thiadiazolylantipyrines, in which thiazolylantipyrine series exhibits better antibacterial
potencies than the thiadiazolylantipyrine series of compounds. In thiazolylantipyrine series
compounds 17 – 19 are well thought-out to be the better active antimicrobial members
recognized in this study with a broad spectrum of antibacterial activity against both Gram
positive and Gram negative bacteria.
Significance of Thiazole-based Heterocycles for Bioactive Systems
http://dx.doi.org/10.5772/62077
9
 Zablotskaya A et al. [72] prepared trimethylsilyl ethers of different hydroxyl group bearing
thiazole compounds. All the compounds examined possess antihypoxic properties and extend
the life of mice under conditions of hypoxia by 20-78%. The silylated and unsilylated deriva‐
tives in the preponderance of circumstances show antihypoxic activity.
 
Dae-Kee K et al. [73] produced a set of 5-(pyridin-2-yl)thiazoles enclosing a para or meta-
carboxamide or carbonitrile-substituted phenylmethylamino moiety at the 2-position of the
thiazole ring and was estimated for activating receptor-like kinase 5 (ALK5) inhibitory activity
in cell-based luciferase publisher assays.
 
Rajan S G et al. [74] designed and synthesized a sequence of 2-(2,4-disubstituted-thiazole-5-
yl)-3-aryl-3H-quinazoline-4-one 23 compounds. Synthesized molecules were estimated for
their inhibitory activity in the course of record factors, nuclear factor-kB (NF-kB) and activating
factor (AP-1) interceded transcriptional activation in a cell line based in vitro assay as well as
for their anti-inflammatory activity in vivo model of severe inflammation.
N
N
O
N
S
NH
R2
R1
Cl
23  
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Johan et al. [75] synthesized a unique sequence for Aurora kinase inhibitors enclosing thiazole
moiety (SNS-314, 24). Also, key SAR as well as essential binding elements has been explained.
 
HI El-Subbagh et al. [76] synthesized a sequence of 2,4-disubstituted thiazole compounds
containing N-n-butyl or N-cyclohexyl thioureido synthon at position-2 and N-substituted
thiosemicarbazone moiety 25 at position-4 and verified for antitumor activity. All of the
established derivatives revealed antineoplastic activity at concentrations less than 102 μM.
μ
α
The unique model of a thiazole in the best 200 drugs citations is cefdinir 26 (Omnicef), a semi-
synthetic third generation cephalosporin that is controlled orally and has a stretched antibac‐
terial activity in contrast to both gram-positive and gram-negative bacteria. The key feature of
cefdinir is that it exhibits outstanding activity against Staphylococcus species [77]. The thiazole
ring in cefdinir reveals that the heterocyclic structure in a drug does not only affect its
pharmacodynamic properties but can also affect its kinetics. It is hypothesized that the
digestive tract iron (II) ions form chelate complexes with the oxime nitrogen atom and thiazole
ring and, therefore, decrease the bioavailability of cefdinir [77].
μ
 
α
The HIV-1 protease inhibitor ritonavir [78] (Norvir 7) contains two different substituted
thiazole rings, which are presented at the advanced steps in the synthesis of this peptidomi‐
metic antiviral compound. Remarkably, ritonavir is a consequence of advanced enhancements
on earlier candidates for the action of AIDS [80].
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The dopamine D2-agonist pramipexole 27 (Mirapex) contains a fused bicyclic tetrahydroben‐
zothiazole design, which is also easy to obtain by a Hantzsch-type condensation reaction
between a α-brominated protected form of 4-aminocyclohexanone and thiourea [81].
 
Famotidine (28, Pepcidine) is one of the top an H2-receptor antagonists, which is equivalent to
cimetidine that prevents various isoenzymes of the hepatic CYP450 system and the additional
side effect (Swelling of the hands, feet or ankles) of enhancing the amount of gastric bacteria
such as nitrate reducing bacteria. The arrangement of this ulcer therapeutic is very enthralling
and contains a thiazole substituted guanidine and a sulfamoyl amidine. Current reports have
performed designated famotidine as a significant ligand for numerous transition metals
containing copper and cobalt developing tetradentate {N, N,S,N}-coordination spheres as
revealed by single X-ray analysis [82]. Therefore, it seems viable that assured frequent
bioavailable cations influence be included in the absorption and initiation of this thiazole
involving compound. The formation of the thiazole ring [83,84] can be able again by conden‐
sation of thiourea with dichloroacetone.
N
SN
H2N
H2N
S
N
H
HN S
O
O NH2
28  
One more example of a thiazole ring enclosing drug is known in the unique xanthine oxidase
inhibitor febuxostat 29 (Uloric) which was accepted by the FDA in 2009 [85]. This inhibitor
works by hindering xanthine oxidase in a non-competitive manner. Subsequently, the quantity
of the oxidation product uric acid is decreased. Thus, it is an extremely well-organized action
for hyperuricemia in gout.
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 Takeuchi et al. described the total synthesis of the cyclic tripeptide bistratamide H 30 estab‐
lished in the procedure of an extremely fluorous amino protecting group and multistep
purifying by F-LPE using FC-72 in which 15 out of the 17 steps were purified by F-LPE [86].
 
The construction of two heterocyclic rings in one synthetic step has been developed for the
preparation of coumarin derivatives. In this process, the thiazole ring (31 – 40) is accomplished
by Hantzsch reaction monitored by fabrication of pyrazole by reacting a 3-(2-bromoacetyl)
coumarin with thiosemicarbazide and acetylacetone at room temperature [87].
 
Adib et al. [88] described, in the latest work, a well-organized three component reaction that
is significant to the formation of essential heterocycles titled by imidazo[1,2-a]thiazoles (41
& 42).
 
S. Zheng et. al. [89] synthesized five series of thiazole derivatives (43 – 47) for fascin therapeutic
target as emerged from cancer cells is thoroughly related to tumor progression and metastasis.
The entire compounds based on thiazole derivatives examined anti-migration and anti-
invasion activities via possible inhibition of fascin function. The five series of analogs with
elongated alkyl chain substitutions on the thiazole nitrogen revealed better anti-migration
activities than those with other structural motifs.
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 J. Zhu et.al. [90] reported that Human dihydroorotate dehydrogenase (HsDHODH) is a flavin-
dependent mitochondrial enzyme that has been specialized as a prospective therapeutic aim
for the medication of rheumatoid arthritis and other autoimmune diseases. On the basis of the
main compound 48, which was earlier recognized as potential HsDHODH inhibitor, a novel
series of thiazole derivatives were designed and synthesized. The complex X-ray structures of
the encouraging referents 49 and 50 established that these inhibitors bind at the recognized
ubiquinone binding channel and directed us to explore additional potent inhibitors, such as
compounds 44, 46, and 47 which exhibited double digit nanomolar activities of 26, 18, and 29
nM, respectively.
 
μ
μ
μ
−
S. Singh et. al. [91] P-glycoprotein (P-gp) works as a therapeutic target for the improvement of
multidrug conflict reversal agents. In this study, we synthesized twenty-one novel derivatives
by peptide coupling at equivalent carboxyl and amino termini of (S)-valinebased bis-thiazole
and mono thiazole derivatives with different chemical scaffolds. Consuming calcein-AM efflux
assay, we recognized compound 51 (IC50 = 1.0 μM) containing 3,4,5-trimethoxybenzoyl and 2-
aminobenzophenone groups, respectively, at the amino and carboxyl termini of the mono
thiazole zwitterion. Compound 51 inhibited the photolabeling of P-gp with [125I] - iodoaryla‐
zidoprazosin with IC50 = 0.75 μM and motivated the basal ATP hydrolysis of P-gp in a
concentration-dependent manner (EC50 ATPase = 0.027 μM).
μ
μ
μ
 
−
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Oridonin 52, a complex molecule ent-kaurane diterpenoid obtained from the traditional
Chinese herb Isodon rubescens, has demonstrated great potential in the treatment of various
human cancers due to its unique and safe anticancer pharmacological profile. However, with
oridonin’s poor solubility and poor bioavailability, hence C. Ding et. al.92 inserted thiazole ring.
The shortest way of synthesis of a series of novel nitrogen contained oridonin derivatives
inserted thiazole-fused A-ring system through an active protecting group-free synthetic
approach is the best of them, including compounds, 53−59 exhibited effective anti-proliferative
effects against breast, pancreatic, and prostate cancer cells with low micromolar to submicro‐
molar IC50 values as well as significantly improved aqueous solubility. These new derivatives
achieved by realistically transforming the natural product have been established not only to
induce considerably the apoptosis and inhibits the growth of triple-negative MDA-MB-231
breast cancer both in vitro and in vivo but also active against drug-resistant ER-positive MCF-7
clones.
 
M. E. D. Francesco et. al. [93] reported a unique type of inhibitor, which designates the
identification of a structurally various series of compounds including a 2-amino-1,3-thiazole
as substitution of the carbamate in P4. Optimization studies motivated on structural variations
in the P3, P2, and P1 regions of the macrocycle as well as on the linked chain caused the
discovery of numerous analogs characterized by outstanding levels of enzyme and cellular
activity. Among these, compound 60 exhibited the best pharmacokinetic profile in preclinical
species and revealed constant liver levels subsequent oral administration in rats.
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P. J. Sanfilippo et. al. [94] reported and described the synthesis and biological activity of a
different kind of thiazole containing heterocycles as inhibitors of thrombin-induced human
platelet aggregation. Additional estimation of selected compounds shows they inhibit platelet
aggregation as motivated by a range of agonists. The highly active compounds also were
established to inhibit fibrinogen binding to platelets. To further explain the mechanism of the
action of these compounds, direct binding studies with the cleaned glycoprotein (GP) IIb/IIIa
receptor were conducted. Flow cytometry analyzes of 61 and 62 designate that these com‐
pounds block the activation process of the GPIIb/IIIa receptor without denaturing the integrin
receptor. On the basis of results, 62 showed the best profile as a novel non-peptide inhibitor
of fibrinogen-mediated platelet aggregation.
 
J. E. M. Koezen et. al. [95] prepared numerous N-[4-(2-pyridyl)thiazol-2-yl]benzamides, and
these compounds exhibited adenosine affinities in the micromolar range. Most unexpected in
the series of the N-[4-(2-pyridyl)thiazol-2-yl]amides were the retained adenosine affinities by
the introduction of a cylopentanamide instead of the benzamide.
Scope of Selective Heterocycles from Organic and Pharmaceutical Perspective16
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P. C. Srivastava et. al. [96] published a report in which they described the glycosylthiocarbox‐
amides were used as the starting compounds for the synthesis of 2-D-ribofuranosylthiazole-4-
carboxamide and 2-β-D-ribofuranosylthiazole-5-carboxamide (76). The structural variation of
2-β-D-ribofuranosylthiazole-4-carboxamide (77) into 2-(2,3,-5-tri-O-acetyl- β-D-ribofurano‐
syl)thiazole-4-carboxamide (78), 2-β-D-ribofuranosylthiazole-4-thiocarboxamide, and 2-(5-
deoxy- β-D-ribofuranosyl)thiazole-4-carboxamide (79) is also designated. These thiazole
nucleosides were verified for in vitro activity against type-1 herpes virus, type-3 parainfluenza
virus, and type-13 rhinovirus and an in vivo test was run against parainfluenza virus. They
were also analyzed as potential inhibitors of purine nucleotide biosynthesis. It was revealed
that the compounds (77 and 79) which influenced the most noteworthy antiviral activity were
also active inhibitors (40-70%) of guanine nucleotide biosynthesis.
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Z. Li et. al. [97] described the virtual screening data for flavivirus envelope proteins (E proteins)
having been exposed to play a vital role in virus assembly, morphogenesis, and infection of
host cells. Inhibition of flavivirus infection of a host cell by utilizing the small molecule
envelope protein antagonist is an interesting approach to the development of antiviral agents.
The virtual screening of the NCI Chemical database utilizing the dengue virus envelope
protein structure showed numerous theoretical hit compounds. Bioassay consequences
recognized a class of thiazole compounds with antiviral potency in cell-based analyzes.
Variation of these lead compounds directed to a series of derivatives with enhanced antiviral
activity and reduced cytotoxicity. The maximum activity exhibit compounds 80 and 81 were
potent in the low micromolar concentration range in a cellular evaluate method.
 
L. J. Lombardo et.al. [98] identified thiazole-based compounds as effective as Src/Abl kinase
inhibitors with outstanding antiproliferative activity against hematological and solid tumor
cell lines. Compound 82 was orally active in a K562 xenograft model of chronic myelogenous
leukemia (CML), establishing complete tumor regressions and very low toxicity at multiple
dose levels. On the basis of its powerful in vivo activity and promising pharmacokinetic profile,
82 was designated for supplementary characterization for oncology manifestations.
 
P. Madsen et. al. [99] explained the thiazole containing scaffold being potent human glucagon
receptor antagonists with enhanced pharmacokinetic (PK) properties for expansion of
pharmaceuticals for the medication of type-2 diabetes. The syntheses of compounds with cyclic
moieties (5-aminothiazoles), their binding affinities for the human glucagon and GIP receptors,
as well as affinities for mouse, pig, rat, dog, and monkey glucagon receptors. Normally, the
compounds had less glucagon receptor affinity corresponding to compounds of the earlier
series slightly, but this was rewarded for by much developed PK summaries in both rats and
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dogs with high oral bioavailabilities and constant high plasma coverages. The compounds
exhibited species selectivity for glucagon receptor binding with very low affinities for the rat,
mouse, rabbit, and pig receptors. However, dog and monkey glucagon receptor affinities seem
to reflect the human situation. One of the compound sequence, 83, was tested intravenously
in an anesthetized glucagon-challenged monkey model of hyperglucagonaemia and hyper‐
glycaemia and was revealed dose-dependently to reduce glycaemia.
N
H
O
HO
O
N
S
N
CF3
Cl
83  
≥
μ μ
μ
μ
μ
X. Cheng et.al. [100] reported a cell-based high throughput screening (HTS) operation for the
search for potential candidates for octamer-binding transcription factor 4 (Oct3/4). In that
process, they recognized numerous efficient small molecules for inducers of Oct3/4 expression.
From HTS, optimized compounds are based on thiazole ring containing scaffold such as ethyl
2-([(4-chlorophenyl) amino])-thiazole-4-carboxylate, 84, exhibiting high activity in implement‐
ing Oct3/4 expression. On the source of chemical expansion, once again screened the recog‐
nized derivatives requiring improved activities in the direction of Oct3/4 induction. Therefore,
84 and its analogs had afforded better potential small molecules proper for an iPSC generation.
 
≥
μ μ
μ
μ
μ
C. P. Hencken et. al. [101] synthesized 23 new dehydroartemisinin (DART) trioxane analogs
in which 11 thiazoles moiety-containing compounds remaining are based on two oxadiazoles,
and ten carboxamides and screened them for in vitro activity in the Toxoplasma lytic cycle.
Fifteen (65%) of the analogs were noncytotoxic to host cells (TD50 ≥ 320 μM). Eight thiazole
compounds exhibited effective inhibition of Toxoplasma growth (IC50 = 0.25-0.42 μM), similar
in potency to artemether (IC50 = 0.31 μM) and >100 times stronger inhibitory than the presently
working front-line drug trimethoprim (IC50 = 46 μM). The thiazoles as a ring were more efficient
than other analogs at the inhibiting progress of extracellular as well as intracellular parasites.
Surprisingly, two thiazole trioxanes (109 and 110) were parasiticidal; both inhibited parasite
replication permanently after parasite contact to 10 μM of the drug for 24 h. However, the
standard trioxane drugs artemisinin and artemether were not parasiticidal.
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Y. Kumar et. al. [102] reported that Methyl-4-(isothiocyanatomethy1)thiazole-2-carbamate
have been obtained via chemical conversion containing 2-amino-4-(chloromethy1)thiazole
(117) as precursor. The homoanalog, methyl 4-(2-isothiocyanatoethyl)thiazole-2-carbamate
was synthesized via (2-aminothiazol-4-y1)acetic acid. All thiazole compounds synthesized
were estimated for their capability to inhibit leukemia L1210 cell proliferation. Methyl 4-
(isothiocyanatomethyl) thiazole-2-carbamate (118) was the active compound in this screen,
inhibiting the growth of L1210 leukemic cells with an IC50 = 3.2 NM. Mitotic blocking performs
to be its key mechanism of cytotoxic activity. Compound 118 furthermore was the only
compound that confirmed important in uiua antifiiarial activity against the adult worms of
Acanthocheilonema uiteae in experimentally infected jirds.
 
μ
New thiazole based compounds [103] (1-(4-arylthiazol-2-yl)-2-(3-methylcyclohexylidene) -
hydrazine) 119 are synthesized for the studied human B isoform of monoamine oxidase. These
compounds were prepared as racemates and (R)-enantiomers by a stereoconservative syn‐
thetic arrangement in high yield and enantiomeric excess. The (S)-enantiomers of the highly
active analogs have been separated by enantioselective HPLC. All compounds showed
selective activity against hMAO-B with IC50 ranging between 21.90 and 0.018 μM.
μ
 
A. S. Mayhoub et.al. [104] synthesized a sequence of third-generation referents of methyl 4-
(dibromomethyl)-2-(4-chlorophenyl)thiazole-5-carboxylate 120, which had the highly potent
antiviral activity comparable to the first and second generation derivatives, have been
synthesized and verified against yellow fever virus consuming a cell-based assay. The
compounds were aimed at the objectives of enlightening metabolic stability, therapeutic index,
and antiviral potency. The biological effects of C4 and C5 substitution were studied. The
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methylthio ester and the dihydroxypropylamide analogs had the effective antiviral potencies
and enhanced therapeutic indices and metabolic stabilities comparative to the parent com‐
pound 120.
 
β
T. A. Dineen et.al. [105] reported the variation in structure 133 for the improved BACE1/CYP
3A4 inhibitors by a P1-phenyl ring of the hydroxyethylamine series to afford potent, which
exhibit enhanced penetration into the CNS. Numerous compounds caused a robust decrease
of Aβ levels in rat CSF and brain subsequently oral dosing, and compound 134 showed a better
cardiovascular safety profile comparative to 133.
β
 
B. Ghosh et.al. [106] reported structure-activity relationship investigated on a unique hybrid
sequence of derivatives where structural modification of aromatic hydrophobic moieties
associated with the piperazine ring and bioisosteric exchange of the aromatic tetralin moieties
were passed out. Binding assays were accepted with HEK-293 cells uttering either D2 or D3
receptors with tritiated spiperone to estimate inhibition constants (Ki). Functional activity of
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designated compounds in stimulating GTPγS binding was evaluated with CHO cells uttering
human D2 receptors and AtT-20 cells uttering human D3 receptors. SAR results recognized
compound 136 as one of the lead molecules with better agonist activity for D3 receptor (EC50
(GTPγS); D3= 0.52 nM; D2/D3 (EC50): 223). Compounds 135 and 136 showed potent radical
scavenging activity, the two lead compounds, 135 and 136, showed more in vivo activity in two
Parkinson’s disease (PD) animal models, reserpinized rat model and 6-OHDA brought
unilaterally lesioned rat model.
γ
γ
 
J. Das et.al. [107] explained that the 2-aminothiazole 137 was established as a unique Src family
kinase inhibitor pattern through high calculated screening of their internal compound
assembly. Optimization through consecutive structure-activity relationship iterations are
recognized analogs 138 (Dasatinib, BMS-354825) and 139 as pan-Src inhibitors with nanomolar
to subnanomolar strengths in cellular and biochemical assays. Molecular modeling techniques
are utilized to conceptualize a recognized binding model for Lck inhibition by this type of
compounds. The oral efficiency of this type of inhibitors was established with 139 in inhibiting
the proinflammatory cytokine IL-2 ex vivo in mice (ED50 ~ 5 mg/kg) and in decreasing TNF
levels in a serious murine model of inflammation. The oral efficiency of 139 was further verified
in a chronic model of adjuvant arthritis in rats with recognized disease when ordered orally
at 0.3 and 3 mg/kg two times daily.
γ
γ
 
Major medicinal chemistry researcher focused on good docking small molecules inhibits the
type 2 diabetes performances to have an insufficient or deficiency in one or both of these
processes. Compounds that can activate glucokinase (GK) may serve as effective treatments
for type 2 diabetes. In this process R. J. Hinklin et al. [108] reported that the recognition and
preliminary optimization of a series of allosteric glucokinase activators (GKAs), revealed an
early thiazolylamino pyridine-based hit that was elevated using a structure-based design
approach and recognized 140 as an early lead. Compound 140 validated a good steadiness of
in vitro effectiveness and enzyme kinetic limits and confirmed blood glucose decreases in oral
glucose patience tests in both C57BL/6J mice and high-fat fed Zucker diabetic fatty rats.
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Spinal muscular atrophy (SMA), an inherited autosomal neurodegenerative disease, is the
foremost genetic disorder disturbing infant mortality. Clinically, there are four kinds of SMA
(types I, II, III, and IV). In fact, SMA is the top one genetic origin of death in children below
the age of two, and several children life have been spoil due to confined to wheelchairs. There
is presently no medication or effective treatment for SMA. Structure-activity relationships
including microsomal stability, cell permeability, and in vivo pharmacokinetics (PK) studies
are necessary. J. Xiao et al. [109] reported SMA active theoretically lead candidate selected from
a sequence may work for as a valuable analysis for exploring the therapeutic aids of SMN
protein up-regulation in SMA animal models and an initial point for clinical improvement.
With regard to all the features including ADME properties, analogs 141 and 142 possessed the
greatest combination of effectiveness, efficiency, mouse liver microsomal steadiness, and cell
permeability of all the analogs that showed good activity.
 
μ
M. D, Rose, et al. [110] discussed the inhibition and antiviral activity consequence synthesis of
14- and 15-membered macrocycles for HIV-1 protease inhibitors (PIs) as obtained by ring-
closing metathesis of the respective linear PIs. The macrocycles were very highly active than
the linear precursors and compound 143, with a 2-thiazolyl ring was the best potent PI of this
new series (Ki 2.2 nM, EC50 = 0.2 μM).
μ
 
The preparation of a sequence of quinazolines inserted at C4 by aminothiazole ring is reported
[111]. Their in vitro structure-activity relationships against Aurora A and B serine-threonine
kinases are examined. The results reveal that quinazolines with a substituted aminothiazole
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at C4 possess potent Aurora A and B inhibitory activity and outstanding selectivity against a
panel of several serine-threonine and tyrosine kinases. Compound 144 also found that the
location and nature of the substituent on the thiazole play vital roles in cellular potency.
 
Approximately, the thiazole ring containing compound exhibits cathepsin K inhibitors [112].
The amalgamation of binding elements resulted at sub-250 pM, reversible, selective, and orally
bioavailable cathepsin K inhibitors. In a series on of the compound exhibited single digit
nanomolar inhibition in vitro (of rabbit osteoclastmediated degradation of bovine bone). The
effective compound in this series, 145 (CRA-013783/ L-006235), was orally bioavailable in rats,
with a terminal half-life of over 3 h, 145 was medicated orally in ovariectomized rhesus
monkeys once per day for 7 days.
 
Haffner et. al. a series of thiazoloquinazolinones [113] were prepared and studied the inhibi‐
tory activity against CD38. Numerous compounds were also revealed to have good pharma‐
cokinetic properties and established the capability to raise NAD levels in plasma, liver, and
muscle tissue. Specifically, compound 146 was agreed to diet induced obese (DIO) C57Bl6
mice, enriching NAD > 5-fold in liver and >1.2-fold in muscle against control animals at a 2 h
time point.
 
Thiazolo[5,4-d]pyrimidines and thiazolo[4,5-d]pyrimidines are structurally mimic with
purines, in which a 1,3-thiazole ring system exchanges the imidazole moiety. While purine
chemistry is broadly discussed in the literature, the number of medicinal chemistry publica‐
tions that reported the synthesis and biological studies of thiazolopyrimidines is narrow
comparable with purines. Seemingly, the thiazolopyrimidine scaffold is not very often used
in drug discovery platforms. However, biological activities of unequivocal thiazolo[4,5-
d]pyrimidines and thiazolo[5,4-d]pyrimidines have been described. A summary of available
compounds with their biological significance is presented in Figures 147, 148, 149 and 150.
Scope of Selective Heterocycles from Organic and Pharmaceutical Perspective24
 Thiazolo[4,5-d]pyrimidine derivative 151 revealed in vivo activity towards a broad range of
RNA and DNA viruses [114] and also had antitumor and antimetastatic activity [115]. The
guanine analogs 152 exhibited potent in vitro activity against human cytomegalovirus
(HCMV) [116]. Thiazolo[4,5-d]pyrimidine-5,7-dione analogs (compound 153) have been
described as having potential anti-inflammatory activities, because of TNF inhibition [117]. 4
2-Oxo-3-arylthiazolo[4,5-d]pyrimidine analogs (compound 154) have been produced as
antagonists of the corticotrophin-releasing hormone (CRH) R1 receptor [118]. 2-Thio-3-aryl-
thiazolo[4,5-d]pyrimidine and its derivatives have been reported as having anticancer
(compound 155) [119], antimicrobial and anti-inflammatory activity (compound 156a &
156b) [120]. 2-Aminothiazolo[4,5-d]pyrimidines (compound 157a & 157b) which performance
as CXCR2 receptor antagonists are also recognized [121]. Lately, 2,7-substituted-thiazolo[4,5-
d]pyrimidines (compound 158) have been explained as ATP-competitive inhibitors of protein
kinase [122].
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2,5-Diaminothiazolo[5,4-d]pyrimidin-7(6H)-one (Compound 159), a thio-isostere of 8-amino‐
guanine, was established to be a poor inhibitor of purine nucleoside phosphorylase (PNP) [123].
7-Diethylamino-5-methylthiazolo[5,4-d]pyrimidine  160  has  vasodilating  and  hypotensive
properties, inhibits platelet aggregation, and decreasing cholesterol levels [124]. Thiazolo[5,4-
d]pyrimidines were enclosed by numerous patent properties such as activators of caspases and
inducers of apoptosis (compound 161) [125], anti-angiogenic agents (compound 162) [126],
growth factor  receptor  inhibitors  (compound 163)  [127],  heat  shock protein  90  (HSP-90)
inhibitors (compound 164) [128], and xanthine oxidase inhibitors (compound 165) [129].
 
5. General Synthetic Routes to Thiazolo[5,4-d]pyrimidines
In wide-ranging, pyrimidines with a nitrogen-containing substituent at position 5 (such as an
amino or nitro group) can work as precursors for the formation of thiazolo[5,4-d]pyrimidines
by thiazole ring condensation. 5-Amino- or 5-nitropyrimidines can be organized from diethyl
amino-, nitro-, or acetylamino-malonate by reacts with coupling reagents such as thiourea
[130], urea [131], guanidine [132] and amidines [133] in alkali conditions. By reaction of the
4,6-dihydroxypyrimidine analog with a thionation reagent (Lawesson’s reagent or phospho‐
rus pentasulfide) in pyridine, alteration of oxygen into sulfur and thiazole ring closure is
accomplished. Interaction of 5-amino-6- mercaptopyrimidines with reagents such as phosgene
[134], formic acid [135], and acid anhydride [136] also gives thiazolo[5,4-d]pyrimidines.
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Thiazolo[5,4-d]pyrimidine-1-N-oxides, ready to obtain from 6-chloro-1,3-dimethyl-5-nitro‐
pyrimidinone by reaction with mercapto compounds, monitored by base catalyzed dehydra‐
tive cyclization, can be simply deoxygenated to produce thiazolopyrimidines. Reductive
deoxygenation by treatment of the thiazolopyrimidine oxides with sodium dithionite or
oxidative deoxygenation with dimethylformamide at reflux temperature can produce the
anticipated thiazolopyrimidines [137].
 
2-Mercaptothiazolo[5,4-d]pyrimidines easily obtained from 6-chloro-5-nitropyrimidines by
the reaction with carbon disulfide and sodium sulfide [138].
 
2-Amino-7-chlorothiazolo[5,4-d]pyrimidines are prepared from 5-amino-4,6-dichloropyrimi‐
dine and isothiocyanate in presence base [139].
 
Ahmed et al. [140] reported the synthesis of thiazolo[5,4-d]pyrimidines from pyrimidines
without 5-amino or 5-nitro substituents. The reaction between 5-bromo-4-thioxo-pyrimidi‐
nones and dimethylcyanamide affords carbodiimide intermediates, which is a very fast
intramolecular cyclization to produce a thiazole ring.
 
On the other hand, thiazolo[5,4-d]pyrimidines also obtained from 5-aminothiazole derivatives,
are prepared from aminomalononitrile (or its derivatives) and isothiocyanates [141] or
thioesters [142]. The next to 5-amino and 4-cyano (or conforming carboxamide or ester groups)
on the thiazole ring are proper functionalities to concept a fused pyrimidine ring system. 7-
Aminothiazolo[5,4-d]pyrimidines can be prepared from 5-amino-4-cyanothiazoles by reaction
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with reagents such as orthoesters and amidines [143,144]. The reaction between 5-amino-4-
carboxamide (or carboxylate) thiazoles and orthoesters [145], formamide [146], and ethyl
chloroformate/DMF [147] gives thiazolo[5,4-d]pyrimidin-7(6H)ones.
 
Additionally, Thiazolo[5,4-d]pyrimidinones readily to obtained from the corresponding
oxazolopyrimidines. In fact, that 1,3-oxazole ring system is quickly converted into a 1,3-
thiazole by a thermal rearrangement. The thioamide replaced oxazole derivative is prepared
from the corresponding amide by reacts with Lawesson’s reagent. Heating generates the nitrile
ylide by electrocyclic ring opening, followed by a 1,5-dipolar electrocyclization affording the
thiazole [148].
 
6. General Synthetic Routes to Thiazolo[4,5-d]pyrimidines
The preparation of thiazolo[4,5-d]pyrimidines from a properly substituted pyrimidine
compound yields 2-aminothiazolo[4,5-d]pyrimidines. Thiocyanation of 6- aminopyrimidines
reacts with potassium thiocyanate, bromine and pyridine, proceeded by cyclization yields the
2-aminothiazolo[4,5-d]pyrimidines [149].
 
Condensation of 5-bromobarbituric acid with thiourea and/or its derivatives in the presence
of an alkali yields thiazolo[4,5-d]pyrimidine derivatives [150].
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 Another significant technique for the preparation of thiazolo[4,5-d]pyrimidines from thiazoles
is via the aza-Wittig reaction [151]. The iminophosphorane intermediates are found from 4-
chloro-5-formylthiazoles which reacts with sodium azide and triphenylphosphine (Staudinger
reaction). In Addition, reaction with isocyanates affords the corresponding carbodiimides,
followed by heating, and undergo an electrocyclic ring closing, which upon a Dimroth-type
rearrangement obtained thiazolo[4,5-d]pyrimidines [152].
 
It is needed to expand the hit ratio in HTS campaigns; fortunate molecular scaffold systems
offer a perfect basis of main compounds. A particular library created on preferable bioisosteres
groups are inserted into the main scaffold and can generate the bioactive compounds in a broad
range of biological tests. Numerous researchers have developed these structures in such a
fashion. For example, Ghorpade and co-workers built a library based on the thiazolopyridines
privileged scaffold [153] whereas Bebernitz and co-workers made use of the chlorosulfonic
acid combined with thiazolopyridines scaffold [154] (compounds 166 and 167)
 
Bicyclic nitrogen, sulfur - containing heterocycles, such as Thiazolo[5,4-b]quinoline, thiazolo‐
pyridines, and thiazolopyrimidines are well-known pharmacophores in drug discovery
[155-157]. Examples of promoted drugs with a bicyclic core structure include AMG-369 analogs
performing as Lysophospholipid edg1 (S1P1) and Receptor Agonists Lysophospholipid edg8
(S1P5) Receptor Agonists [158]. Thiazole sulfonamides based scaffold, used as antidepressants
and for the treatment of Vasopressin (AVP) V1b Antagonists [159]. Kirsch and co-workers
described a solution-phase synthesis of 7-amino-thiazolo[4,5-b]pyridine derivatives [160] as
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well as fused-pyridine analogs such as the thiopheno[2,3-b]pyridines [161] using the Fried‐
lander reaction.
Thiazolo[4,5-b]pyridine derivatives reveal a broad range of biological properties. For example,
thiazolo[4,5-b]pyridines have confirmed actions as serine protease factor Xa (fXa) inhibitors
for thrombosis [162], as metabotropic glutamate receptor 5 (mGluR5) antagonists for several
CNS syndromes [163], as histamine H3-receptor antagonists for epilepsy and Alzheimer’s
disease [164], as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors [165], and
as cAMP phosphodiesterase (PDE) III inhibitors for congestive heart catastrophe [166].
T. Lee et. al. [167] reported a series of 2,5,6,7-tetrasubstituted thiazolo[4,5-b]pyridine deriva‐
tives (168) from solid-phase synthesis. Thorpe-Ziegler type cyclization of solid supported
cyanocarbonimidodithioate with α-halo ketones gave thiazole resin, which were transformed
to the preferred thiazolopyridine resin by the Friedlander procedure under microwave
irradiation conditions. After oxidation of sulfides to sulfones, nucleophilic desulfonative
substitution with amines yielded the target thiazolo[4,5-b]pyridine derivatives.
α
 
−
α
α
Y. Takahashi et. al [168] described the synthesis and structure−activity relationships of a unique
series of 7-dialkylamino-3-phenyl-6-methoxy pyrazolo[5,1-b]thiazole derivatives to utilize as
selective antagonists of the corticotropin-releasing factor 1 (CRF1) receptor. The best favorable
compound, N-butyl-3-[4-(ethoxymethyl)-2,6-dimethoxyphenyl]-6-methoxy-N-(tetrahy‐
dro-2H-pyran-4-yl)pyrazolo-[5,1-b, 1,3]thiazole-7-amine (169), exhibited very high affinity
(IC50 = 70 nM) and functional antagonism (IC50 = 7.1 nM) for the human CRF1 receptor.
α
−
 
α
α
7. Summary
This chapter discusses the high synthetic perspective of several methods for synthesis of
thiazoles and its derivatives that have been published in the last three decades. Many pharma‐
ceutically active heterocycles have been obtained based on the reaction of acid hydrazides
particularly concerning Hantzsch reaction, Dimroth type rearrangement, Tchernich reaction,
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CooK–Heilbron reaction, Gabriel reaction, Erlenmeyer reaction, Hartke–Seib reaction and Dubs
reaction. Fundamentally α-halo carbonyl compounds and substituted thiourea or thiosemicar‐
bazide are potential precursors for the creation of wide range of thiazole analogous as main
synthon constituents for generation of several diverse heterocycles. The aza-Wittig product
such  as  iminophosphorane  intermediates  obtained  from  4-chloro-5-formylthiazoles  by
treatment with sodium azide and triphenylphosphine (Staudinger reaction) with most other
various reagents like isocyanate, isothiocyanate and carbondisulfide for bicyclic generation
system containing thiazole moiety under basic, acidic or neutral reaction conditions. Most of
these reagents are available from simply or commercially accessible, inexpensive precursors.
This chapter has also verified the noticeable feature to the advancement of an eco-friendly
experimental  technique  for  the  synthesis  of  heterocyclic  compounds.  The  synthetic  ap‐
proaches showed in this chapter can be comprehensive to the synthesis of natural macrocy‐
clic thiazole ring containing heterocycles and also suggest that α-halo carbonyl compounds can
be  a  favorable  building  block  in  combinatorial  synthesis  of  functionalized  heterocyclic
derivatives used for the design of unique very active pharmaceutical drugs with a broad
spectrum of bioresponses. In certain cases, reports on the less yield of bioactive heterocycles in
this chapter could be overwhelmed by forthcoming synthetic chemists with this sustained
research and new methods for extensive approach and explained experimental procedures
could be explored for its development for generation of a library of such multi-functional
heterocycles to afford a useful encouragement to medicinal chemistry.
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